GAINSBOROUGH

WELLINGTON

STOKE

PARKGATE

TYNEMOUTH

SCUNTHORPE

DERBY

CRIBBS CAUSWAY

JARROW

LETCHWORTH

RIPON HARROGATE ROAD

LIVINGSTON DEDRIDGE

CROWBOROUGH

ABERDEEN KING ST

AYR CASTLEHILL RD

EAST KILBRIDE STEWAR

LARGS IRVINE RD

ORMSKIRK PARK RD

PENRITH OLD LOCATION

WHITEHAVEN FLATT WAL

BELPER CHAPEL STREET

EVESHAM FOUR POOL

HEREFORD COMMERCIAL

NANTWICH STATION RD

NEWCASTLE UL GOOSSE

SOLIHULL GEORGE ROAD

WALSALL LICHFIELD ST

BANGOR HOLYHEAD RD

CARMARTHEN LLANELLI

COLWYN BAY SEA VIEW

EASTWOOD WESTERN APP

HADLEIGH LONDON RD

LONDON CAMDEN TOWN

LONDON SHEPHERDS BUSH

LONDON WOOD GREEN

LONDON PECKHAM

ST ALBANS HATFIELD

TAVISTOCK PLYMOUTH

WESTON SUPER MARE

FARNBOROUGH SOUTHWOOD

GOSPORT WALPOLE RD

HASTINGS QUEENS RD

HORNDEAN LAKESMERE RD

PORTSMOUTH ANCHORAGE

REIGATE BELL ST

SEAFORD DANE RD

SWINDON HAYDON WICK

LIVINGSTON CARMONDEA

SOLIHULL SHIRLEY

WOKINGHAM WOOSEHILL

BRENTFORD

COWDENBEATH

Clinova’s O.R.S soluble tablets will be available in over 10,000 UK pharmacies from June, 2012. O.R.S soluble tablets are one of the world’s first tablet forms of the standard oral rehydration salts formula. The tablets contain a combination of glucose, salts and electrolytes. The tablets help to replenish the body with water and salts that have been depleted due to dehydration and thereby help to maintain an optimal fluid balance. O.R.S soluble tablets are designed for a variety of users including people who lose excess fluid, professional and recreational athletes, visitors to hot/tropical countries and people who are dehydrated due to alcohol consumption.  The usual dosage form for oral rehydration salts is a sachet but Clinova’s tablet form offers significant advantages compared to existing sachet form products. Clinova’s oral rehydration salts soluble tablets are a glucose-salt combination. If the body loses more fluid than it takes in e.g. in exercise or heat exhaustion, this can result in dehydration. To enable the intestines to obtain fluid from food residues, glucose and minerals are important.  The effervescent tablets replenish the water and body salts and thereby help to maintain a proper fluid balance.  This product will be available from almost all pharmacies in England, Wales, Northern Ireland and Scotland.

Clinova’s leadership team led by Co-founder and Director of Research and Development, Arsalan Karim will be available to meet partners and industry leaders at the World Economic Forum annual meeting in Davos which begins on the 25^th of January, 2012 and continues till the 29^th of January, 2012.

For further information about meeting our team, please contact our information department with your details,

info@clinova.co.uk

Stemaderm™ is a novel 100% natural skincare cream. The unique formula is based on a combination of natural ingredients that work synergistically to provide a beneficial skincare action. The patent will provide Stemaderm™ with long term protection and security in key markets.

For further information about the patent, please contact our information department with your request,

info@clinova.co.uk

Andrew qualified at Sunderland School of Pharmacy and trained as Pharmacist with Boots the Chemist. Andrew owns the AlChem Pharmacy Group. He was elected to the National Pharmacy Association Board of Management in April 2010 to represent the South West and became Vice Chairman in April 2011. Andrew is the South West Regional Representative for Pharmaceutical Services Negotiating Committee and is an active member of Gloucestershire Local Pharmaceutical Committee and was recently elected to NHS Gloucestershire PEC.  He is a pharmacist member of the Primary Care Cardio Vascular Society and has interest in developing local networks of pharmacists keen to deliver services to Primary Care Commissioning organizations. Andrew will provide Clinova with strategic advise on the rollout of our new OTC products for the UK pharmacy market. He is also active in Europe as member of the Alliance Healthcare European Forum and an early advocate of Alphega Pharmacy, the virtual chain concept developed by Alliance Healthcare.

Clinova aims to produce a liquid remedy that includes a X2030 as its principal ingredient. The product will be indicated to help with the management of Indigestion and Dyspepsia. Clinova’s research programme will develop the formulation and conduct all clinical development work to help launch the product globally.